Is MariMed A Safe Haven In The Wake Of Florida's Cannabis Legalization Defeat?
Is MariMed A Safe Haven In The Wake Of Florida's Cannabis Legalization Defeat?
在佛羅里達州大麻股合法化失敗之際，MariMed是否成爲一個安全的避風港？
Cannabis company MariMed Inc. (NASDAQ:MRMD) released its Q3 2024 results on November 6, announcing revised guidance for the fiscal year. While the company expects an 18–20% decline in EBITDA – down from its prior projection of flat to 2% growth – it raised its sales guidance to a 6–8% increase, up from 5–7%. These adjustments align closely with earlier projections from Zuanic & Associates, a cannabis industry research firm.
大麻公司MariMed Inc. (納斯達克：MRMD)於11月6日發佈了2024財年第三季度的業績，宣佈修正了財政年度的指導方針。雖然公司預計EBITDA將下降18%至20%——低於之前預測的持平至2%的增長——但它將銷售指導方針提高至6%至8%的增長，上調自5%至7%。這些調整與大麻行業研究公司Zuanic & Associates之前的預測密切相關。
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. You can't afford to miss out if you're serious about the...
在Benzinga獲取獨家分析，並每天免費獲得關於大麻業務和市場的頭條新聞。立...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。